Search Result

Results for "

FASN

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Fatty Acid Synthase (FASN) (27) Antibiotic (2) Apoptosis (6) Bacterial (2) Fungal (1) SARS-CoV (2) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (22) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (2) Metabolic Disease (9)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: Fatty Acid Synthase (FASN)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12648A

FASN-IN-4 tosylate 3 Publications Verification	Fatty Acid Synthase (FASN) SARS-CoV	Infection Metabolic Disease
FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (FASN) with an IC₅₀ of 10 nM (WO2012064642A1, compound 29) . FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC₅₀ of 18.6 nM .

HY-145809

FASN-IN-5	Fatty Acid Synthase (FASN)	Metabolic Disease Inflammation/Immunology Cancer
FASN-IN-5 (example 11), a *FASN* inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer, immunological disorders, and obesity .

HY-111777

FASN-IN-1

1 Publications Verification

Fatty Acid Synthase (FASN) Cancer

FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56 .
HY-U00436

FASN-IN-3

Fatty Acid Synthase (FASN) Cancer

FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A .

FASN-IN-1 1 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56 .

FASN-IN-3	Fatty Acid Synthase (FASN)	Cancer
FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A .

HY-12648

FASN-IN-4	Fatty Acid Synthase (FASN) SARS-CoV	Infection Metabolic Disease
FASN-IN-4 is a potent inhibitor of fatty acid synthase (FASN) with an IC₅₀ of 10 nM (WO2012064642A1, compound 29) . FASN-IN-4 also inhibits SARS-CoV-2 with an EC₅₀ of 18.6 nM .

HY-155282

FASN-IN-6	Fatty Acid Synthase (FASN) Bacterial	Inflammation/Immunology
FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively .

HY-RS04753

FASN Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FASN Human Pre-designed siRNA Set A contains three designed siRNAs for FASN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FASN Human Pre-designed siRNA Set A FASN Human Pre-designed siRNA Set A

HY-RS04754

Fasn Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fasn Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fasn gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fasn Mouse Pre-designed siRNA Set A Fasn Mouse Pre-designed siRNA Set A

HY-RS04755

Fasn Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fasn Rat Pre-designed siRNA Set A contains three designed siRNAs for Fasn gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fasn Rat Pre-designed siRNA Set A Fasn Rat Pre-designed siRNA Set A

HY-112829

Denifanstat 1 Publications Verification TVB-2640; FASN-IN-2; ASC-40	Fatty Acid Synthase (FASN)	Metabolic Disease Cancer
Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC₅₀ of 0.052 μM and an EC₅₀ of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research .

HY-121250

Fasnall	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Fasnall is a selective fatty acid synthase (FASN) inhibitor with an IC₅₀ of 3.71 μM. Fasnall induces apoptosis in HER2 ⁺ breast cancer cell lines. Fasnall shows potent anti-tumor activities .

HY-B0218

Orlistat 5+ Cited Publications Tetrahydrolipstatin; Ro-18-0647	Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease Cancer
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .

HY-110354

UCM05 G28UCM	Fatty Acid Synthase (FASN) Bacterial Antibiotic	Infection Cancer
UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. UCM05 is a Filamentous temperature-sensitive protein Z (FtsZ) inhibitor and inhibits the growth of the Gram-positive bacterium B. subtilis with MIC values of 100 μM but lack activity on the Gram-negative bacterium E. coli.

HY-111551

FT113 1 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
FT113 is a potent and orally active fatty acid synthase (FASN) inhibitor, with an IC₅₀ of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC₅₀, 90 nM). FT113 shows anti-proliferative activity, and exhibits anti-cancer activity both in vitro and in vivo .

HY-117769

GSK837149A	Fatty Acid Synthase (FASN)	Metabolic Disease
GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on *FASN* and selectivity for type I *FASN* (K_i=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer .

HY-120394

TVB-3166 5+ Cited Publications	Fatty Acid Synthase (FASN) Apoptosis	Cancer
TVB-3166 is an orally-available, reversible, and selective fatty acid synthase (FASN) inhibitor with IC₅₀s of 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis, respectively. TVB-3166 induces apoptosis, and inhibits in-vivo xenograft tumor growth .

HY-12364A

trans-C75

(±)-C75
Fatty Acid Synthase (FASN) Cancer

trans-C75 ((±)-C75) is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (FASN) inhibitor.

trans-C75 (±)-C75	Fatty Acid Synthase (FASN)	Cancer
trans-C75 ((±)-C75) is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (FASN) inhibitor.

HY-112522

HS79	Fatty Acid Synthase (FASN)	Cancer
HS-79 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-79 is able to inhibit the incorporation of tritiated acetate into lipids with an IC₅₀ of 1.57 μM.

HY-112522A

HS80	Fatty Acid Synthase (FASN)	Cancer
HS-80 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-80 is able to inhibit the incorporation of tritiated acetate into lipids with an IC₅₀ of 7.13 μM.

HY-12364

C75 Maximum Cited Publications 21 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM . C75 is a potent CPT1A activator .

HY-N2486

Desoxyrhaponticin 1 Publications Verification	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.

HY-124628

IPI-9119	Fatty Acid Synthase (FASN)	Cancer
IPI-9119 is an orally active, selective and irreversible *FASN* inhibitor with an IC₅₀ of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models .

HY-12364B

(−)-C75	Fatty Acid Synthase (FASN)	Cancer
(−)-C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM . C75 is a potent CPT1A activator .

HY-A0210

Cerulenin 5 Publications Verification	Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic	Infection Metabolic Disease
Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies .

HY-120062

TVB-3664 1 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
TVB-3664 is an orally available, reversible, potent, selective and highly bioavailable fatty acid synthase (FASN) inhibitor, with IC₅₀ values of 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively. TVB-3664 significantly reduces tubulin palmitoylation and mRNA expression .

HY-B0218R

Orlistat (Standard) 5+ Cited Publications Tetrahydrolipstatin (Standard); Ro-18-0647 (Standard)	Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease Cancer
Orlistat (Standard) is the analytical standard of Orlistat. This product is intended for research and analytical applications. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity .?Anti-atherosclerotic?effect .

HY-12325

GSK2194069 2 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
GSK2194069 is a potent inhibitor of β-ketoyl reductase (KR) of fatty acid synthase (FASN), with an IC₅₀ value of 7.7 nM. GSK2194069 shows specifically inhibitory effect on FAS expressing cancer cells, by acting potent efficacy on acetoacetyl-CoA, NADPH with IC₅₀ or K_i values of 4.8 nM and 5.6 nM, respectively .

HY-16100

BI 99179 1 Publications Verification	Fatty Acid Synthase (FASN)	Metabolic Disease Cancer
BI 99179 is a potent and selective type I fatty acid synthase (FAS) inhibitor with an IC₅₀ of 79 nM. BI 99179 is a tool compound suitable for the in vivo validation of FAS as a target for lipid metabolism related diseases. BI 99179 exhibits significant exposure (both peripheral and central) upon oral administration in rats .

HY-149540

CTL-06	Fatty Acid Synthase (FASN)	Cancer
CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC₅₀: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

HY-149541

CTL-12	Fatty Acid Synthase (FASN)	Cancer
CTL-12 is an inhibitor of fatty acid synthase (FASN) (IC₅₀: 2.5 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

HY-N8144

Niga-ichigoside F1	Others	Cardiovascular Disease
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .

Cat. No.	Product Name

HY-L091

Lipid Metabolism Compound Library	650 compounds
Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation. MCE offers a unique collection of 650 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

Lipid Metabolism Compound Library

650 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 650 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

Desoxyrhaponticin 1 Publications Verification	Structural Classification Monophenols Stilbenes Classification of Application Fields Polygonaceae Source classification Rheum rhabarbarum Linnaeus Phenols Plants Disease Research Fields Rheum tanguticum Cancer	Fatty Acid Synthase (FASN) Apoptosis
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.

Cerulenin 5 Publications Verification	Structural Classification Microorganisms Antifungal Classification of Application Fields Antibiotics Source classification Metabolic Disease Mammalian Cell Culture Disease Research Anticancer Disease Research Fields Other Antibiotics	Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic
Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies .

Niga-ichigoside F1	Cardiovascular Disease Triterpenes Inula sericophylla Franch. Classification of Application Fields Terpenoids Labiatae Source classification Plants Disease Research Fields	Others
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701881

	FASN Protein, Human (Sf9) FASN; Fatty acid synthase; Type I fatty acid synthase; [Acyl-carrier-protein] S-acetyltransferase; [Acyl-carrier-protein] S-malonyltransferase; 3-oxoacyl-[acyl-carrier-protein] synthase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-hydroxyacyl-[acyl-carrier-protein] dehydratase; Enoyl-[acyl-carrier-protein] reductase; Acyl-[acyl-carrier-protein] hydrolase	Human	Sf9 insect cells
	FASN (fatty acid synthase) is a multifunctional enzyme that is key to the de novo biosynthesis of long-chain saturated fatty acids from acetyl-CoA and malonyl-CoA using NADPH. This multifunctional protein contains seven catalytic activities and has an acyl carrier protein (ACP) domain with a binding site for the prosthetic group 4'-phosphopantetheine. FASN Protein, Human (Sf9) is the recombinant human-derived FASN protein, expressed by Sf9 insect cells , with tag free. The total length of FASN Protein, Human (Sf9) is 416 a.a., .

HY-P701882

	FASN Protein, Human (Sf9, His) FASN; Fatty acid synthase; Type I fatty acid synthase; [Acyl-carrier-protein] S-acetyltransferase; [Acyl-carrier-protein] S-malonyltransferase; 3-oxoacyl-[acyl-carrier-protein] synthase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-hydroxyacyl-[acyl-carrier-protein] dehydratase; Enoyl-[acyl-carrier-protein] reductase; Acyl-[acyl-carrier-protein] hydrolase	Human	Sf9 insect cells
	FASN (fatty acid synthase) is a multifunctional enzyme that is key to the de novo biosynthesis of long-chain saturated fatty acids from acetyl-CoA and malonyl-CoA using NADPH. This multifunctional protein contains seven catalytic activities and has an acyl carrier protein (ACP) domain with a binding site for the prosthetic group 4'-phosphopantetheine. FASN Protein, Human (Sf9, His) is the recombinant human-derived FASN protein, expressed by Sf9 insect cells , with N-8*His labeled tag. The total length of FASN Protein, Human (Sf9, His) is 416 a.a., .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Application	Reactivity

HY-P80668

Fatty Acid Synthase Antibody (YA766) FASN; FAS; Fatty acid synthase	WB, ICC/IF, IP	Human, Mouse, Rat, Monkey
Fatty Acid Synthase Antibody (YA766) is a non-conjugated and Mouse origined monoclonal antibody about 273 kDa, targeting to Fatty Acid Synthase (2F9). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat, Monkey.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks